Specialty Pharmacy ContinuumMedicaid Cuts, Federal Policy Shifts Threaten 340B Rx Price Eligibility

⚖️ Legal / Ethical Complexity

Medicaid losses under the One Big Beautiful Bill Act are lowering disproportionate share hospital percentages at safety-net hospitals, directly threatening 340B eligibility. Manufacturer contract pharmacy restrictions and a court-halted HRSA rebate model are compounding program risk from multiple directions simultaneously.

Professional Impact

• OBBBA Medicaid cuts will reduce Medicaid inpatient days, pushing DSH percentages below the 11.75% eligibility threshold in high-impact states, including projected enrollment losses of 10%–15% in Arizona and 12% in Kentucky.
• The HRSA rebate pilot, injuncted Dec. 29, 2025 and now under RFI, is expected to return in revised form, requiring upfront WAC purchases with 45-day rebate claim windows that outpace most institutions’ revenue cycle timelines.
• IRA drug price negotiation currently involves 58 NDCs across 10 negotiated drugs, consuming more than 50 staff hours weekly for rebate tracking at participating institutions, with annual list expansion anticipated.
• State contract pharmacy protection laws offer partial relief but face manufacturer litigation in every state that has enacted them, producing jurisdiction-by-jurisdiction legal uncertainty.

Action Items

• Track DSH percentage monthly; model how service-line expansions affect Medicaid inpatient day calculations before committing to growth decisions.
• Establish IT data feeds and cash buffers now to support WAC-upfront purchasing and 45-day rebate claim submission under the anticipated revised rebate model.
• Audit NDC crosswalks for all IRA-negotiated drugs and dedicate staff to weekly reconciliation before the negotiated drug list expands.
• Engage state pharmacy associations to advance contract pharmacy protection legislation and quantify the patient-care services 340B savings fund.